-
公开(公告)号：WO2023061723A1
公开(公告)日：2023-04-20
申请号：PCT/EP2022/076442
申请日：2022-09-22
Applicant: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) , UNIVERSITAT DE BARCELONA , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS , PROVINCIAL HEALTH SERVICES AUTHORITY
Inventor： SALVATELLA GIRALT, Xavier , RIERA ESCALÉ, Antoni , FRIGOLÉ VIVAS, Marta , SÁNCHEZ ZARZALEJO, Carolina , RUFFONI, Alessandro , VERDAGUER ESPAULELLA, Francesc Xavier , SADAR, Marianne Dorothy , BANUELOS, Carmen Adriana , MAWJI, Nasrin
IPC: A61K31/09 , A61K31/519 , A61P5/26 , A61P5/28 , A61P35/00
Abstract: The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
-
2.发明申请
公开(公告)号：WO2018229057A1
公开(公告)日：2018-12-20
申请号：PCT/EP2018/065519
申请日：2018-06-12
Applicant: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
IPC: A61K45/06 , A61K31/337 , A61K31/437 , A61K31/4418 , A61K31/4745 , A61K31/7048 , G01N33/574 , A61P35/00
CPC classification number: A61K45/06 , A61K31/337 , A61K31/437 , A61K31/4418 , A61K31/4745 , A61K31/7048 , A61P35/00 , G01N33/57415 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to compositions comprising a specific p38α inhibitor and an agent that induces chromosome instability, wherein the specific p38α inhibitor has a half maximal inhibitory concentration (IC50) equal to or less than 40 nM. The invention also relates to the above compositions or to a specific p38α inhibitor for use in the treatment of breast cancer, wherein the breast cancer is characterised by a high degree of aneuploidy. Finally, the invention relates to a method for identifying a breast cancer patient who responds to a treatment with the above compositions or with a specific p38α inhibitor, wherein the breast cancer is characterised by a high degree of aneuploidy, and a method for selecting a treatment for a breast cancer patient.
-
3.发明申请TARGETING METASTASIS STEM CELLS THROUGH A FATTY ACID RECEPTOR (CD36) 审中-公开通过脂肪酸受体靶向METASTASIS干细胞（CD36）
公开(公告)号：WO2017055411A1
公开(公告)日：2017-04-06
申请号：PCT/EP2016/073208
申请日：2016-09-29
Applicant: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
Inventor： AZNAR BENITAH, Salvador , PASCUAL ANGULO, Gloria , CASTELLANOS MARTIN, Andres , MARTIN PEÑA, Merce
IPC: C07K16/28 , C07K16/30 , G01N33/574 , C12N15/11 , A61K39/00
CPC classification number: C07K16/2896 , A61K2039/505 , C07K16/30 , C12N15/1138 , C12N2310/14 , C12N2310/531 , G01N33/57484 , G01N2333/70596 , G01N2500/00
Abstract: Targeting metastasis stem cells through a fatty acid receptor. The disclosure provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.
Abstract translation: 通过脂肪酸受体靶向转移干细胞。 本公开提供了用于治疗口腔鳞状细胞癌（OSCC）的CD36活性或表达的阻断剂或抑制剂的用途，特别是用于治疗产生的转移并且减少是原发性肿瘤的产生。 除了shRNA之外，还提供了抗CD36抗体作为阻断剂或抑制剂，特别是那些阻断CD36与氧化型LDL和脂肪酸结合并将其掺入细胞的抗CD36抗体，因为促进其运输是CD36促进的机制 转移传播和生长。 还提供了一种用于鉴定抗癌剂候选物的方法，特别是用于OSCC转移的候选物，在体内或体外在CD36 +细胞中促进的抗癌药物的候选物，与CD36消耗或阻断相关的作用，例如脂滴的生长积累的减少和 在转移的情况下的大小。
-
4.发明申请
公开(公告)号：WO2023046283A1
公开(公告)日：2023-03-30
申请号：PCT/EP2021/076120
申请日：2021-09-22
Applicant: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) , UNIVERSITAT DE BARCELONA , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS , PROVINCIAL HEALTH SERVICES AUTHORITY
Inventor： SALVATELLA GIRALT, Xavier , RIERA ESCALÉ, Antoni , FRIGOLÉ VIVAS, Marta , SÁNCHEZ ZARZALEJO, Carolina , RUFFONI, Alessandro , VERDAGUER ESPAULELLA, Francesc Xavier , SADAR, Marianne Dorothy , BANUELOS, Carmen Adriana , MAWJI, Nasrin
IPC: A61K31/09 , A61K31/519 , A61P5/26 , A61P5/28 , A61P35/00
Abstract: The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
-
5.发明申请
公开(公告)号：WO2016207626A1
公开(公告)日：2016-12-29
申请号：PCT/GB2016/051864
申请日：2016-06-22
Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH , UNIVERSITAT DE BARCELONA , THE UNIVERSITY OF MANCHESTER , FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA)
Inventor： VENDRELL ESCOBAR, Marc , SUBIROS FUNOSAS, Ramon , MENDIVE TAPIA, Lorena , ALBERICIO PALOMERA, Fernando , LAVILLA GRIFOLS, Rodolfo , READ, Nick D.
CPC classification number: A61K49/0021 , C07F5/02 , C07F5/022
Abstract: The invention relates to compounds, particularly fluorogenic amino acid derivatives, which can be used as optical probes. The invention further relates to processes for the preparation of such compounds, the use of such compounds as probes and methods of detecting a target using such compounds as probes.
Abstract translation: 本发明涉及可用作光学探针的化合物，特别是荧光氨基酸衍生物。 本发明还涉及制备这些化合物的方法，使用这种化合物作为探针和使用这些化合物作为探针来检测靶的方法。
-
Patent Agency Ranking
公开(公告)号：WO2022200621A1
公开(公告)日：2022-09-29
申请号：PCT/EP2022/058030
申请日：2022-03-25
Applicant: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
Inventor： SALVATELLA GIRALT, Xavier , BIESAGA, Mateusz , FRIGOLÉ VIVAS, Marta
Abstract: The present invention provides a drug discovery assay to screen for compounds capable of modulating condensates based on the ability of the said compounds to shift the condensation propensity of a studied target, preferably an intrinsically disordered protein.
-
公开(公告)号：WO2021063972A1
公开(公告)日：2021-04-08
申请号：PCT/EP2020/077272
申请日：2020-09-29
Applicant: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) , FUNDACIÓ INSTITUT MAR D'INVESTIGACIONS MÈDIQUES (FIMIM) , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
Inventor： CALON, Alexandre , IGLESIAS COMA, Mar , BATLLE GÓMEZ, Eduard , SANCHO SUILS, Elena , BERENGUER LLERGO, Antonio
IPC: G01N33/574 , C12Q1/6886
Abstract: The present invention relates to a new biomarker useful to identify cancer patients with a TGFβ-activated microenvironment in colorectal cancer and other tumor types. It further relates to methods of predicting response to inhibitors of the TGFβ signaling pathway and methods of classification and selection of cancer patients for treatment with inhibitors of the TGFβ signaling pathway, to prognostic methods, to methods of monitoring or evaluating response to inhibitors of the TGFβ signaling pathway and to related second medical uses, diagnostic kits and uses thereof.
-
8.发明申请NUCLEIC ACID CONSTRUCTS AND VECTORS FOR ONCOSELECTIVE EXPRESSION OF A TRANSGENE 审中-公开转录后反义表达的核酸构建体和载体
公开(公告)号：WO2017153606A1
公开(公告)日：2017-09-14
申请号：PCT/EP2017/055836
申请日：2017-03-13
Applicant: FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS , INSTITUT D’INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS)
IPC: A61K35/761 , C12N15/85 , C12N15/86
CPC classification number: C12N15/85 , A61K35/761 , C12N15/86 , C12N2710/10332 , C12N2710/10343 , C12N2710/10345 , C12N2800/24 , C12N2840/007 , C12N2840/102
Abstract: The invention relates to a nucleic acid construct comprising polynucleotide of interest and an untranslated 3' sequence including at least two cytoplasmic polyadenylation elements. The invention also relates to vectors, viral particles, cells and pharmaceutical compositions comprising said nucleic acid construct, and to their use for inducing selective expression of a polynucleotide in a tumor cell, and said nucleic acid construct for use in medicine and in the treatment of cancer.
Abstract translation: 本发明涉及包含目标多核苷酸和包含至少两个细胞质聚腺苷酸化元件的未翻译3'序列的核酸构建体。 本发明还涉及包含所述核酸构建体的载体，病毒颗粒，细胞和药物组合物，以及它们用于诱导肿瘤细胞中多核苷酸选择性表达的用途，以及所述核酸构建体用于医学和治疗 癌症
-
9.发明申请TRANSITION METAL PHOSPHINO-OXAZOLINE CATALYSTS, PROCESSES FOR THEIR PRODUCTION, AND USES THEREOF IN THE HYDROGENATION OF CYCLIC ENAMIDES AND IMINES 审中-公开过渡金属磷酸 - 氧杂环丁烷催化剂，其生产方法及其在循环利用和加氢反应中的应用
公开(公告)号：WO2016203005A1
公开(公告)日：2016-12-22
申请号：PCT/EP2016/064064
申请日：2016-06-17
Inventor： RIERA ESCALÉ, Antoni , VERDAGUER ESPAULELLA, Francesc Xavier , ORGUÉ GASSOL, Silvia , SALOMÓ PRAT, Ernest
CPC classification number: C07F9/46 , C07B53/00 , C07F5/022 , C07F15/0033
Abstract: The present invention relates to a complex of the Formula 2, and a compound of Formula 1, and the use of said compound of Formula 1 for the synthesis of said complex of Formula 2, processes for synthesis of said compound of Formula 1, and use of said complex of Formula 2 in asymmetric hydrogenation of cyclic enamides and imines
Abstract translation: 本发明涉及式2的络合物和式1化合物，以及所述式1化合物用于合成所述式2配合物的方法，所述式1化合物的合成方法和用途 所述式2的复合物在环酰胺和亚胺的不对称氢化中
-
公开(公告)号：WO2014191559A1
公开(公告)日：2014-12-04
申请号：PCT/EP2014/061278
申请日：2014-05-30
Applicant: INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS , FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA)
Inventor： BATLLE GÓMEZ, Eduard , SANCHO SUILS, Elena , ROSSELL RIBERA, David , CALON, Alexandre , ESPINET HERNÁNDEZ, Elisa , PALOMO PONCE, Sergio
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
Abstract: The invention relates to methods for predicting the risk of relapse of cancer patients as well as methods for providing personalized medicine to said patients based on the expression levels of different genes the expression of which is induced in response to TGF-beta stimulation. The invention also relates to kits for carrying out the diagnostic and predictive medicine methods.
Abstract translation: 本发明涉及用于预测癌症患者复发风险的方法以及用于基于不同基因的表达水平向所述患者提供个性化药物的方法，所述不同基因的表达响应于 TGF-β刺激。 本发明还涉及用于执行诊断和预测药物方法的试剂盒。
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.027 seconds)
